Axon shares fall as RBC cuts price target on federal deal delays
RBC Capital cut Axon Enterprise's (AXON) price target to $615 from $735, citing delayed federal Dedrone deals and margin pressures. AXON shares fell 10% this week, trading 32% below their 52-week high. Despite challenges, the company reported 34.6% revenue growth and 20% year-to-date bookings growth. Piper Sandler and Needham also lowered their price targets but maintained positive ratings.
How this was made
The 30-second read
Why it matters
Analyst target cuts reflect concerns over timing risk of large federal deals, potentially weighing on the stock in the short term.
Market read
Multiple analyst downgrades on the same day as an earnings miss suggest immediate downside risk for AXON.
What to watch
Strong software ARR growth and high gross margins may cushion earnings volatility.
Background
AXON reported a 28% YoY revenue increase but missed EPS and sales expectations due to delayed federal Dedrone contracts.
Ticker impact
RBC lowered AXON's price target to $615 and Piper Sandler and Needham also cut targets after the company missed Q3 earnings expectations.
likely pressure as the market prices in weaker guidance and reduced federal contract revenue.
Multiple analysts cut targets on the same day the earnings miss was disclosed, indicating a consensus view of lower near‑term valuation.
Market effects
Federal‑contract software and hardware vendors may see broader scrutiny as procurement delays affect revenue forecasts.
U.S. tech stocks with significant government contracts could face heightened volatility.
Limited to U.S. markets; no immediate global ripple.
Counterpoint
If the delayed deals eventually materialize, AXON could rebound, making the cuts premature.
Key entities
- analystRBC Capital
Reduced price target to $615, maintaining Outperform.
- analystPiper Sandler
Lowered price target to $540, maintaining Overweight.
- analystNeedham
Cut price target to $500, maintaining Buy.

